Determinants of Variation in the Use of Adjuvant Chemotherapy for Stage III Colon Cancer in England
- 1 May 2020
- journal article
- research article
- Published by Elsevier in Clinical Oncology
- Vol. 32 (5) , e135-e144
Abstract
No abstract availableKeywords
Funding Information
- Medical Research Council (MR/S020470/1)
This publication has 41 references indexed in Scilit:
- Adherence to Stage-Specific Treatment Guidelines for Patients With Colon CancerJournal of Clinical Oncology, 2012
- Comparison of adverse events during 5‐fluorouracil versus 5‐fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancerCancer, 2012
- Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapyCritical Reviews in Oncology/Hematology, 2011
- American Society of Anaesthesiologists physical status classificationIndian Journal of Anaesthesia, 2011
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson ScoreBritish Journal of Surgery, 2010
- Rates and predictors of chemotherapy use for stage III colon cancerCancer, 2008
- The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United StatesAnnals of Surgical Oncology, 2008
- Completion of Therapy by Medicare Patients With Stage III Colon CancerJNCI: Journal of the National Cancer Institute, 2006
- Explaining Black–White Differences in Receipt of Recommended Colon Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2005